TNF inhibitorReviewed for 2026 plan year

Does Kaiser Permanente Cover Enbrel?

The verdict

Covered on most plans

Kaiser Permanente covers Enbrel on its closed formulary with prior authorization and step therapy, with all prescribing and dispensing handled inside the Kaiser integrated system. Step therapy typically routes through a preferred TNF or adalimumab biosimilar first, since no etanercept biosimilar is marketed — Erelzi and Eticovo are FDA-approved but legally blocked until April 24, 2029. For Kaiser Medicare members, Enbrel's CMS-negotiated price is effective January 1, 2026.

MedicareCovered
CommercialCovered
See the difference

Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Kaiser Permanente using your member ID.

Reviewed for 2026
Checked against the active plan year
Sourced from formularies
Kaiser Permanente drug lists + CMS guidance
Updated as rules change
Coverage and prior-auth criteria shift often
Verify before you decide
Informational only — not insurance advice
  • No etanercept biosimilar will be available in the US until April 24, 2029 — Erelzi and Eticovo are FDA-approved but blocked by patent litigation protecting Amgen's US Patent 8,163,522.

    Center for Biosimilars; US District Court for the District of New Jersey, November 2021

  • Enbrel is one of the first 10 Medicare Part D drugs with a CMS-negotiated price; negotiated prices took effect January 1, 2026.

    CMS Medicare Drug Price Negotiation Program, August 2023

  • Kaiser's closed integrated model means Enbrel is prescribed, authorized, and dispensed entirely within Kaiser — no outside specialist or specialty pharmacy is permitted.

    Kaiser Permanente integrated care model / formulary

Medicare vs. commercial coverage

Whether Kaiser Permanente covers Enbrel depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.

Medicare

Part D & Advantage plans

Covered

Medicare (Kaiser Senior Advantage Part D): Enbrel is covered on Kaiser's formulary with PA and step therapy, dispensed through Kaiser's internal specialty pharmacy. Enbrel is one of the first 10 Medicare Part D drugs with a CMS-negotiated price, effective January 1, 2026, which lowers the program's drug cost. The 2026 Part D out-of-pocket cap of $2,100 limits the Medicare member's annual exposure. Coinsurance is typically 25–33% after the deductible. Kaiser's manufacturer savings-card policies within the closed system may be more restrictive — verify with your Kaiser plan.

Commercial / Employer

Group & marketplace plans

Covered

Commercial/Employer (Kaiser HMO): Enbrel is covered on Kaiser's closed formulary with PA and internal step therapy, dispensed by Kaiser's own specialty pharmacy. Members must see a Kaiser rheumatologist, dermatologist, or specialist — no external prescribers or specialty pharmacies. Step therapy typically requires a trial of a preferred TNF inhibitor or adalimumab biosimilar first; no etanercept biosimilar is available (blocked to 2029), so the step agent is not an etanercept product. ACA/Individual (Kaiser marketplace): covered with PA where offered in Kaiser service areas. Medicaid (Kaiser Medi-Cal/managed): covered for approved indications per contract with PA; nominal cost-share.

The 5 boxes you must tick to get approved

Commercial plans that will consider Enbrel require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.

Requirements you meet0 / 5

0 of 5 requirements selected. Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.

Your cost, three ways

What Enbrel actually costs you swings enormously depending on how it's covered. Here's the realistic range.

No coverage

Paying cash

List price approximately $2,039.40 per 50 mg weekly syringe, approximately $8,150/month per Amgen (estimate). Treat as estimate — verify with pharmacy.

List price with no coverage — before any manufacturer savings card.

PA approved

With coverage

Kaiser plan cost-share per member plan (copay or coinsurance per Kaiser plan design). Kaiser Medicare: typically 25–33% coinsurance after the deductible, capped at $2,100 for the year (2026 Part D OOP limit); CMS-negotiated price effective 1/1/2026 lowers program cost. Medicaid: nominal cost-share per Kaiser Medi-Cal contract.

Typical monthly copay once prior authorization is approved.

Lowest cost

Bridge program

Manufacturer savings cards (Enbrel Support program) are generally not usable within Kaiser's closed system — verify with your Kaiser plan. Kaiser Medicare beneficiaries are not eligible for manufacturer assistance programs. Patients experiencing financial hardship should contact Kaiser member services or Amgen's patient-assistance program.

Reduced copay through the assistance program, where eligible.

All figures are estimates. Cost-share varies by Kaiser plan. Confirm your specific out-of-pocket cost with your Kaiser plan before starting treatment.

Check YOUR exact coverage in 3 steps

General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.

  1. 1

    Request a referral to a Kaiser rheumatologist or specialist

    Coverage and PA for Enbrel within Kaiser starts with a referral to a Kaiser rheumatologist, dermatologist, or other specialist for your indication (RA, psoriatic arthritis, plaque psoriasis, etc.). Your Kaiser primary-care physician can initiate this referral.

  2. 2

    Check Kaiser's drug formulary online

    Log in to kp.org and use the drug lookup tool to confirm Enbrel's status on your specific Kaiser plan. You can view tier placement, PA requirements, and step-therapy prerequisites. Contact Kaiser member services at the number on your member ID card for plan-specific details.

  3. 3

    Have your Kaiser specialist submit the internal prior authorization

    Your Kaiser rheumatologist or specialist will submit the PA through Kaiser's internal process, including diagnosis documentation, step-therapy history (prior biologics tried), and clinical rationale. Because Kaiser is a closed system, the PA, dispensing, and follow-up all happen within the Kaiser network.

Options if Kaiser Permanente won't cover Enbrel

A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.

Adalimumab biosimilars (Amjevita, Hyrimoz, others)

Adalimumab biosimilars are the likely step-therapy option Kaiser requires before Enbrel. They are available at lower cost than branded Humira and may be Kaiser's preferred TNF inhibitor on its closed formulary. Ask your Kaiser rheumatologist.

Methotrexate (MTX)

A first-line conventional DMARD for RA and psoriatic arthritis, typically covered at low cost on Kaiser's formulary. Documented MTX trial and failure is commonly required before any biologic DMARD is approved.

Amgen EnSpring patient support (non-Kaiser Medicare)

Amgen's Enbrel Support program offers copay assistance for eligible commercially insured patients outside Kaiser's closed system. Not applicable within Kaiser or for Medicare beneficiaries. Contact Amgen at 1-888-4ENBREL for details.

These options are listed for information only — your own clinician decides what is appropriate for you.

Frequently Asked Questions

This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Kaiser Permanente before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.